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Development of a UK national 
prescribing sKills assessment
S. Maxwell*
Clinical Pharmacology Unit, University of Edinburgh, Edinburgh, 
United Kingdom
Summary: Prescribing of medicines is the key clinical activity in the 
working life of most doctors. In recent years, a broad consensus 
regarding the necessary competencies has been achieved. Each of 
these is a complex mix of knowledge, judgment, and skills. Surveys 
of those on the threshold of their medical careers have revealed wide-
spread lack of confidence in writing prescriptions. A valid and reli-
able assessment of prescribing competence, separate from an overall 
assessment of medical knowledge and skill, would have many benefits 
for clinical governance and patient safety, and would provide a meas-
ure of the success of training programs in therapeutics. Delivering 
such an assessment presents many challenges, not least of which 
are the difficulty in identifying a surrogate marker for competent 
prescribing in clinical practice and the challenge of ensuring that com-
petence assessed in a controlled environment predicts performance 
in clinical practice. This talk will describe the approach being used 
in the United Kingdom to develop an online “OSCE” assessment 
of prescribing and sets out the requirements for its development, 
scope, composition, and delivery. It will describe the current status in 
the development and implementation of the UK national Prescribing 
Skills Assessment for final-year medical students.
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novel antiDiabetics: shoUlD they be UseD 
at all—anD in whom?
C. Meier1,2*
1Department of Medicine, Triemli Hospital, Zurich; and 
2University of Geneva Medical School, Geneva, Switzerland
Summary: During the past few years, several new classes of anti-
diabetic drugs have appeared on the market, such as glucagon-like-
peptide analogs, dipeptidyl peptidase-4 inhibitors, renal glucose 
reuptake inhibitors, and insulin analogues with different kinetic 
properties. Although these drugs have mostly very attractive modes 
of action, their use in clinical practice can be limit by nonsuperiority 
with regard to existing treatments, and increased costs, as well as the 
lack of knowledge on hard end points and long-term safety. This is of 
particular concern with regard to cardiovascular protection or risks, 
as has become evident from the past experience, for example, with 
rosiglitazone. A possible solution to this problem is to individualize 
antidiabetic therapy by taking into account the age, obesity, renal 
function, and therapeutic compliance, as well as other factors of 
the patient, with the aim of choosing drugs that offer individualized 
additional benefits for selected patients.
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assessment of DrUg-inDUceD liver injUry 
from clinical trial Data
M. Merz*
Discovery and Investigative Safety, Novartis Institutes for 
BioMedical Research, Basel, Switzerland
Summary: Proper analysis of liver safety data is multivariate by 
nature and has to take into account time dependency of observa-
tions. Current standard tools for liver safety assessment are summary 
tables, individual data listings, narratives, and static graphs. An effi-
cient complementary approach is use of interactive graphics, ideally 
in a team-based setting. A systematic workflow including predefined 
graph templates helps to ensure completeness of evaluations, sup-
ports hypothesis generation and testing, and facilitates identification 
of the most suitable graphics for publishing and regulatory reporting. 
The use of interactive graphics instead of focusing on static graphs 
enables a project team to jointly assess biomarker data, helps to 
thoroughly query the data from different perspectives, and fosters 
team ownership of both analysis and conclusions. This talk presents 
a systematic workflow for liver safety assessment using a series of 
interactive graph templates.
Disclosure of Interest: None declared.
Development of aDr reporting  
anD monitoring in china
Y. Min*
Department of Drug Safety & Inspection, State Food and Drug 
Administration, Beijing, China
Summary: Today, drugs play an important role in human disease 
prevention and treatment, as well as protection of health. In China, 
along with the development of medicines and the health care system, 
rational drug use and drug safety are becoming increasingly impor-
tant concerns. In the early 1980s, the Chinese government started to 
carry out pilot projects to monitor ADR. In March 1998, we formally 
joined the WHO International Drug Monitoring Program. After 
nearly 20 years of practice, China ADR monitoring was strength-
ened in terms of legal framework, monitoring systems, information 
technology application, administrative control, capital investment, 
and other aspects. Although China’s ADR monitoring has devel-
oped rapidly, we still face many challenges. The revised edition of 
“Management Measures of Adverse Drug Reactions Reporting and 
Monitoring” had been promulgated in July 2011, with the intent to 
further standardize the requirements and procedures of ADR report-
ing. We also intend to intensify the verification, investigation, and 
evaluation of case reports. We also continue to strengthen exchange 
and communication with WHO and other countries on drug safety 
information. We hope to learn best practices and encourage innova-
tion in China’s ADR monitoring system to ensure rational and safe 
use of drugs.
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sjögren ocUlar Disease treatment
L. Módis*
Department of Ophthalmology, University of Debrecen, 
Debrecen, Hungary
Summary: Sjögren’s syndrome is a systemic autoimmune disease 
that results in tear film instability, hyperosmolarity, chronic irrita-
tion, and inflammation of the ocular surface. Treatment can be 
either conservative or invasive based on the severity of the disease. 
The basic aim of the treatment is to improve the quality of life and 
reduce subjective complaints and objective ocular surface irrita-
tion. The first line of treatment is tear substitution with artificial 
tear drops, gels, and ointments. In moderate cases, preservative-
free tear supplementation, topical anti-inflammatory therapy, and 
retinol treatment is recommended. Temporary or permanent punc-
tal plug occlusion, therapeutic contact lenses, or using a moisture 
chamber can also be an option. In severe cases, the application 
of topical autologous serum, systemic anti-inflammatory therapy, 
androgen substitution, secretagogues, and surgical intervention can 
be effective. As a future perspective, causal therapy of the disease 
will play a greater role, such as cyclosporine therapy, secretion 
stimulation, growth factor containing artificial tears, and immu-
nomodulants.
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acaDemia isn’t so baD either
N.D. Moore*
Pharmacology, Univ Bordeaux, Bordeaux, France
Summary: Drug development follows a very specific path, from 
preclinical safety and quality ascertainment to clinical development 
to market authorization and postmarketing surveillance. The whole 
process is geared to the pharmaceutical industry, which indeed has 
all the know-how and experience to bring a drug to market, espe-
cially when it is also the originator of the future drug. When the 
product is derived from academic research, can academia initiate 
drug development, and at what stages? This will depend on the 
availability of the appropriate resources in the academic and/or 
private sectors, and the funding for these. Preclinical drug devel-
opment is not overly expensive, especially for the basic elements 
needed to pursue drug development and to bring the drug to clini-
cal testing. If the quality issues can be controlled (drug synthesis, 
stability testing), basic toxicity testing can be outsourced to any 
of many specialized companies. Obviously, academic laboratories 
should have all the required resources for pharmacodynamic testing 
and demonstration. Clinical trials can be done in the appropriate 
clinical investigation centers, and the academic hospitals of course 
have all the patients needed for the clinical trials, because this is 
usually where industry actually does them. Therefore, academia 
(including public hospitals and research centers) has all the required 
knowledge and resources needed to develop a drug and bring it to 
market. What may be most lacking at the premarket phase is financ-
ing, and finding this is not easy, especially at the later-phase clinical 
trials, which are usually multicenter and require heavy logistical 
resources. Recently developed networks and structures (E-CRIN, 
F-CRIN) aim to help these large multicenter studies. Increasing 
awareness by the public research-financing bodies of the need to be 
able to develop alternatives to industrial development, especially for 
certain types of drugs (drugs for rare diseases or new uses for old 
drugs), may also increase the involvement of academia in de novo 
drug development. Of course, public–private partnerships should 
continue, both through involvement of industry expertise during 
academia-initiated development and through the increasingly evi-
dent involvement of academia during later-phase clinical develop-
ment of major new drugs, if only to avoid unnecessary suspicions of 
industrial misconduct, much as is done in the postmarketing arena 
with the ENCEPP code of conduct.
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role of membrane transporters  
in DrUg interactions
M. Niemi*
Clinical Pharmacology, University of Helsinki and HUSLAB, 
Helsinki University Central Hospital, Helsinki, Finland
Summary: Transporters are membrane proteins, which medi-
ate the translocation of chemicals into and out of cells. The past 
10 years have seen an enormous increase in research concerning 
the role of membrane transporters in drug pharmacokinetics and 
response.1 In particular, influx and efflux transporters expressed 
on the plasma membranes of polarized cells in tissues important 
for pharmacokinetics have the potential to significantly affect 
drug response. Certain transporters have been shown to mediate 
clinically important drug interactions. For example, the immuno-
suppressive drug cyclosporine increases the systemic exposure to 
all statins, by ~5- to 20-fold, probably mainly by inhibiting their 
organic anion transporting polypeptide (OATP)-mediated hepatic 
uptake.3 Similarly, cyclosporine raises the systemic exposure to 
the OATP1B1 substrate antidiabetic repaglinide by 2.5-fold.2 
Furthermore, the P-glycoprotein efflux transporter-inhibiting anti-
mycotic itraconazole raises the systemic exposure to the antihy-
pertensive aliskiren on average 6.5-fold.4 These and other roles of 
OATPs, P-glycoprotein. and other membrane transporters in drug 
interactions will be discussed.
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overview of pharmacovigilance  
in resoUrce limiteD settings:  
challenges anD opportUnities
S. Olsson*
Pharmacovigilance, Uppsala Monitoring Centre, Uppsala, Sweden
Summary: Twenty years ago, there were almost no pharmacovigi-
lance (PV) activities in low-and middle-income countries (LMIC). 
Today, 144 countries are participating in the WHO Programme 
for International Drug Monitoring, and 102 of them belong to the 
LMIC category according to the World Bank classification. Many 
factors have contributed to the positive development. Among them 
are:
-  Creation of evidence of the general burden of drug-related harm 
in all populations
-  Concerns of the high prevalence of substandard and fake medicines 
in LMIC
-  Capacity building and competence development in PV, mainly 
driven by the WHO Programme
-  Public health programs realizing that drug-related harm may jeop-
ardize program success
-  Global health initiatives and donor organizations prepared to 
protect public health programs also by supporting pharmacovigi-
lance
Most of the national pharmacovigilance systems in LMIC still 
have inadequate capacity to adequately protect their populations 
from the risk of medicine and medicine use–related harm. There are 
many challenges that need to be addressed; for example:
-  The capacity of National Regulatory Authorities and collaboration 
and integration with vertical disease programs
-  Training of health workers, local industry, and the public about the 
need to record and report medicine-related harm
- Keeping of systematic patient records
-  Documentation of the burden of medicine-related harm in the local 
setting
In most LMICs, the first requisite for PV activities, the politi-
cal will, is in place. Further support for the young PV systems is 
needed to make them fully functional. The WHO Programme builds 
regional and global networks to support PV in LMIC particularly 
